The Impact of Local Control on Overall Survival After Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jul 13

PMID 39001464

Authors

John Yeakel

Steven N Seyedin

Garrett Harada

Garo Hagopian

Sharmeen Mahmood

Rebecca Bennett

Jeremy P Harris

Elliot M Abbott

Sydney Lindner

Farshid Dayyani

Varun Sehgal

Jeffrey V Kuo

Nadine Abi-Jaoudeh

Affiliations

Soon will be listed here.

Abstract

Y-90 Selective Internal Radiotherapy (SIRT) is an ablative therapy used for inoperable liver metastasis. The purpose of this investigation was to examine the impact of local control after SIRT on overall survival (OS) in oligometastatic patients. A retrospective, single-institution study identified oligometastatic patients with ≤5 non-intracranial metastases receiving unilateral or bilateral lobar Y-90 SIRT from 2009 to 2021. The primary endpoint was OS defined from Y-90 SIRT completion to the date of death or last follow-up. Local failure was classified as a progressive disease at the target lesion(s) by RECIST v1.1 criteria starting at 3 months after SIRT. With a median follow-up of 15.7 months, 33 patients were identified who had a total of 79 oligometastatic lesions treated with SIRT, with the majority histology of colorectal adenocarcinoma ( = 22). In total, 94% of patients completed the Y-90 lobectomy. Of the 79 individual lesions treated, 22 (27.8%) failed. Thirteen patients received salvage liver-directed therapy following intrahepatic failure; ten received repeat SIRT. Median OS (mOS) was 20.1 months, and 12-month OS was 68.2%. Intralesional failure was associated with worse 1 y OS (52.3% vs. 86.2%, = 0.004). These results suggest that intralesional failure following Y-90 may be associated with inferior OS, emphasizing the importance of disease control in low-metastatic-burden patients.

References

van den Hoven A, Rosenbaum C, Elias S, W A M de Jong H, Koopman M, Verkooijen H . Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases. J Nucl Med. 2016; 57(7):1014-9. DOI: 10.2967/jnumed.115.166942. View

Dewaraja Y, Devasia T, Kaza R, Mikell J, Owen D, Roberson P . Prediction of Tumor Control in Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics. J Nucl Med. 2019; 61(1):104-111. PMC: 6954459. DOI: 10.2967/jnumed.119.226472. View

Franzese C, Comito T, Vigano L, Pedicini V, Franceschini D, Clerici E . Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clin Breast Cancer. 2020; 20(6):480-486. DOI: 10.1016/j.clbc.2020.05.006. View

Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E . Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018; 29(12):1662-1670.e4. DOI: 10.1016/j.jvir.2018.07.006. View

Schonewolf C, Patel B, Gensure R, Narra V, Haffty B, Nosher J . Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization. Am J Clin Oncol. 2013; 37(3):234-40. DOI: 10.1097/COC.0b013e318277d610. View

Dunfee B, Riaz A, Lewandowski R, Ibrahim S, Mulcahy M, Ryu R . Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol. 2009; 21(1):90-5. DOI: 10.1016/j.jvir.2009.09.011. View

Tsang E, Loree J, Davies J, Gill S, Liu D, Ho S . Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Can J Gastroenterol Hepatol. 2020; 2020:5104082. PMC: 7704205. DOI: 10.1155/2020/5104082. View

Abbott A, Kim R, Hoffe S, Arslan B, Biebel B, Choi J . Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015; 14(3):146-53. DOI: 10.1016/j.clcc.2015.02.002. View

Wasan H, Gibbs P, Sharma N, Taieb J, Heinemann V, Ricke J . First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3.... Lancet Oncol. 2017; 18(9):1159-1171. PMC: 5593813. DOI: 10.1016/S1470-2045(17)30457-6. View

10.

Kennedy A, Coldwell D, Nutting C, Murthy R, Wertman Jr D, Loehr S . Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006; 65(2):412-25. DOI: 10.1016/j.ijrobp.2005.12.051. View

11.

Milano M, Katz A, Zhang H, Okunieff P . Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2011; 83(3):878-86. DOI: 10.1016/j.ijrobp.2011.08.036. View

12.

Kurilova I, Beets-Tan R, Flynn J, Gonen M, Ulaner G, Petre E . Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. Clin Colorectal Cancer. 2018; 18(1):8-18. PMC: 6884072. DOI: 10.1016/j.clcc.2018.08.004. View

13.

Glazer E, Tseng J, Al-Refaie W, Solorzano C, Liu P, Willborn K . Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010; 12(6):427-33. PMC: 3028584. DOI: 10.1111/j.1477-2574.2010.00198.x. View

14.

Allard M, Adam R, Giuliante F, Lapointe R, Hubert C, IJzermans J . Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017; 117(5):604-611. PMC: 5572175. DOI: 10.1038/bjc.2017.218. View

15.

Spina J, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R . Expected and Unexpected Imaging Findings after Y Transarterial Radioembolization for Liver Tumors. Radiographics. 2019; 39(2):578-595. DOI: 10.1148/rg.2019180095. View

16.

Saxena A, Meteling B, Kapoor J, Golani S, Morris D, Bester L . Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol. 2014; 22(3):794-802. DOI: 10.1245/s10434-014-4164-x. View

17.

Schatka I, Tschernig M, Rogasch J, Bluemel S, Graef J, Furth C . Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. Cancers (Basel). 2021; 13(15). PMC: 8345060. DOI: 10.3390/cancers13153777. View

18.

Padia S, Kwan S, Roudsari B, Monsky W, Coveler A, Harris W . Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014; 25(7):1067-73. DOI: 10.1016/j.jvir.2014.03.030. View

19.

Mee S, Polan D, Dewaraja Y, Cuneo K, Gemmete J, Evans J . Stereotactic body radiation therapy (SBRT) following Yttrium-90 (Y) selective internal radiation therapy (SIRT): a feasibility planning study usingY delivered dose. Phys Med Biol. 2023; 68(6). PMC: 10001703. DOI: 10.1088/1361-6560/acbbb5. View

20.

Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt H . Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014; 14:810. PMC: 4230526. DOI: 10.1186/1471-2407-14-810. View